miRNAs are small non-coding molecules that influence numerous physiological processes through their activity. Among these is bone remodeling, where they regulate the balance between bone resorption and formation.
The aim of this study was to identify and evaluate the target genes of hsa-miR-375-3p, which was previously identified at the Department of Clinical Biochemistry, Faculty of Pharmacy as a differentially expressed miRNA upon exposure of mesenchymal stem cells to the osteoanabolic drug teriparatide. Through bioinformatic analysis, we identified the target genes FZD4 and BMPR2, which are involved in signaling pathways related to bone remodeling. We designed mutated and wild type constructs of both genes and inserted them into pmirGLO plasmids. These plasmids were cotransfected together with hsa-miR-375-3p mimics into HeLa and HOS cell lines. We used a luciferase assay to validate the interaction between hsa-miR-375-3p and the target genes.
We confirmed the interaction between hsa-miR-375-3p and FZD4 in the HOS cell line, while no such interaction was observed in the HeLa cell line. In the HeLa cell line, hsa- miR- 375- 3p bound with higher affinity to the mutated BMPR2 sequence than to the wild-type BMPR2 sequence. This suggests that the introduced BMPR2 gene mutation may represent a genetic risk factor for the development of bone diseases. In contrast in the HOS cell line, no interaction was observed between hsa-miR-375-3p and BMPR2.
Based on our results, we concluded that hsa-miR-375-3p potentially plays a role in bone remodeling, as it interacted with the FZD4 gene, which is part of Wnt/β-catenin signaling pathway that primarily influence the development and function of osteoblasts and bone formation.
|